GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Korea Arlico Pharm Co Ltd (XKRX:260660) » Definitions » Selling, General, & Admin. Expense

Korea Arlico Pharm Co (XKRX:260660) Selling, General, & Admin. Expense : ₩88,492 Mil (TTM As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is Korea Arlico Pharm Co Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Korea Arlico Pharm Co's selling, general, & admin. expense for the three months ended in Mar. 2025 was ₩21,661 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Mar. 2025 was ₩88,492 Mil.


Korea Arlico Pharm Co Selling, General, & Admin. Expense Historical Data

The historical data trend for Korea Arlico Pharm Co's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Korea Arlico Pharm Co Selling, General, & Admin. Expense Chart

Korea Arlico Pharm Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 60,405.12 68,948.95 83,656.47 95,104.91 88,850.95

Korea Arlico Pharm Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22,022.79 22,140.87 21,557.90 23,131.60 21,661.44

Competitive Comparison of Korea Arlico Pharm Co's Selling, General, & Admin. Expense

For the Drug Manufacturers - Specialty & Generic subindustry, Korea Arlico Pharm Co's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Korea Arlico Pharm Co's Selling, General, & Admin. Expense Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Korea Arlico Pharm Co's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Korea Arlico Pharm Co's Selling, General, & Admin. Expense falls into.


;
;

Korea Arlico Pharm Co Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩88,492 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Korea Arlico Pharm Co  (XKRX:260660) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Korea Arlico Pharm Co Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Korea Arlico Pharm Co's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Korea Arlico Pharm Co Business Description

Traded in Other Exchanges
N/A
Address
7-21, Baumoe-ro 27-gil, Seocho-gu, Seoul, KOR
Korea Arlico Pharm Co Ltd is engaged in the business of manufacturing and selling pharmaceuticals products. The company offers products in the area of the circulatory system, antiplatelet, muscle relaxants, diabetes, antibiotic and chemotherapy, allergy and respiratory disease, ointment, vitamin and health supplements, digestive system, and metabolic disease. It provides products in various forms such as tablets, capsules, gel, and cream.

Korea Arlico Pharm Co Headlines

No Headlines